The University of Split is a university located in Split, Croatia. It was founded in 1974. and is organized in 13 faculties and 124 faculty programmes. As of 2009, a total of approximately 40,000 students have graduated, and a total of 337 doctoral degrees have been awarded.University of Split is a member of the following associations: EUA - European University Association, International Associacion of Universities, UNIMED - Unione delle Università del Mediterraneo. Wikipedia.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2013.2.3.3-1 | Award Amount: 31.38M | Year: 2014
Far from receding, the threats posed by infections with epidemic potential grow ever greater. Although Europe has amongst the best healthcare systems in the world, and also the worlds supreme researchers in this field, we lack co-ordination and linkage between networks that is required to respond fast to new threats. This consortium of consortia will streamline our response, using primary and secondary healthcare to detect cases with pandemic potential and to activate dynamic rapid investigation teams that will deploy shared resources across Europe to mitigate the impact of future pandemics on European health, infrastructure and economic integrity. If funded, PREPARE will transform Europes response to future severe epidemics or pandemics by providing infrastructure, co-ordination and integration of existing clinical research networks, both in community and hospital settings. It represents a new model of collaboration and will provide a one-stop shop for policy makers, public health agencies, regulators and funders of research into pathogens with epidemic potential. It will do this by mounting interepidemic (peace time) patient oriented clinical trials in children and in adults, investigations of the pathogenesis of relevant infectious diseases and facilitate the development of sophisticated state-of-the-art near-patient diagnostics. We will develop pre-emptive solutions to ethical, administrative, regulatory and logistical bottlenecks that prevent a rapid response in the face of new threats. We will provide education and training not only to the members of the network, but also to external opinion leaders, funders and policy makers thereby streamlining our future response. By strengthening and integrating interepidemic research networks, PREPARE will enable the rapid coordinated deployment of Europes elite clinical investigators, resulting in a highly effective response to future outbreaks based on solid scientific advances.
Popovic D.,Goethe University Frankfurt |
Vucic D.,Genentech |
Dikic I.,University of Split
Nature medicine | Year: 2014
Ubiquitination is crucial for a plethora of physiological processes, including cell survival and differentiation and innate and adaptive immunity. In recent years, considerable progress has been made in the understanding of the molecular action of ubiquitin in signaling pathways and how alterations in the ubiquitin system lead to the development of distinct human diseases. Here we describe the role of ubiquitination in the onset and progression of cancer, metabolic syndromes, neurodegenerative diseases, autoimmunity, inflammatory disorders, infection and muscle dystrophies. Moreover, we indicate how current knowledge could be exploited for the development of new clinical therapies.
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-EJD | Phase: MSCA-ITN-2015-EJD | Award Amount: 3.86M | Year: 2016
Our aim is to create, in Europe, an innovative and ambitious multidisciplinary intersectoral joint doctoral training programme, dedicated to Methods in Research on Research (MIROR) in the field of clinical research. Research on Research, is an emerging new scientific discipline that aims to reduce waste in research and increase research value. Waste in research represents tens of billions of Euros spent each year on studies that are redundant, flawed in their design, never published or poorly reported. The public is the main victim of this waste and reducing waste and increasing value of research represents a major societal challenge. Our proposal involving 15 early-stage researchers, aims to 1) prepare students for envisioning the future challenges in clinical research and find innovative solutions to face them, 2) train students to go well beyond the state-of-the-art in their research, 3) help students think differently, taking advantage of the multidisciplinary expertise and intercultural diversity of the network, 4) teach students how to move from research to action and convert knowledge and idea into a product, and 5) help students develop skills to match the public and private sector needs and create new professional opportunities. MIROR will bring together 7 world-class research teams in various disciplines (computer sciences, applied mathematics, biostatistics, bioinformatics, clinical epidemiology, psychology, social sciences and translational medicine) from 6 different European countries; 6 non-academic partners involved in diverse sectors, and 4 major academic partners. We will tackle several steps of a clinical research project (planning, conduct, reporting and the peer-review); various study designs (observational studies, randomised trials, systematic reviews); various study questions (therapeutic, diagnostic, and prognostic evaluation) using various methods (meta-epidemiologic studies, qualitative studies, experimental studies, simulations etc).
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: SEC-2013.5.1-1 | Award Amount: 5.13M | Year: 2014
In a disaster situation three things contribute to a success: having the right resource available in the shortest time, with the highest relevance and at the right location. Access to necessary information, communication with other rescuers and stakeholders as well as the availability of resources are key factors in minimizing damage and loss of life. Large scale disasters and crisis situations increase the requirements on man and material exponentially. Additional challenges, in particular in cross border events, include language barriers, knowhow and organizational barriers and technical barriers (communication and data exchange). To address this challenge it will be necessary to analyse three defining factors: 1. Past responses to critical events and disasters in terms of time and cost 2. The data and data management tool used by crisis managers and first responders 3. The organisational structures of the crisis managers and first responders This analysis will enable the definition of a concept for a common information space. A requirement for a successful pan European information space is the definition of a common taxonomy. The common information space, which implies an EU wide standardization activity, will widen the EU wide market for organization developing solutions and tools for crisis management.
Agency: European Commission | Branch: H2020 | Program: FCH2-RIA | Phase: FCH-01.2-2015 | Award Amount: 3.26M | Year: 2016
Fuel-Cell Electric Buses (FCEBs) have been deployed in multiple demonstrations in Europe, Canada and the USA, but they still suffer from high costs and low availability. Oddly enough, the low availability has almost always been due to control issues and hybridisation strategies rather than problems in the fuel cells themselves. Giantleap aims to increase the availability and reduce the total cost of ownership of FCEBs by increasing the lifetime and reliability of the fuel cell system; this will be achieved with advanced online diagnostics of the fuel cells and the balance-of-plant components of the system, coupled with prognostics methods to calculate the systems residual useful life, and advanced control algorithms able to exploit this information to maximise the systems life. The same control system will also be engineered for robustness, in order to increase availability to the level of diesel buses or better. Giantleap will improve the understanding of degradation in fuel-cell systems with extensive experimentation and analysis; diagnostic and prognostic methods will focus on exploitation of current sensors to make the novel control approach cost-effective. Giantleap includes the demonstration of a prototype in relevant environment, allowing the project to reach technology readiness level 6. The prototype will be a trailer-mounted fuel-cell based range extender meant for battery city buses. The ability to swap out the range extender in case of malfunctions greatly increases the availability of the bus, while the large battery capacity allows the bus to complete its route should malfunctions occur during usage. Furthermore, the large battery capacity will give the control system ample opportunity to optimise fuel-cell usage via hybridisation management strategies.
Agency: European Commission | Branch: H2020 | Program: FCH2-RIA | Phase: FCH-02.5-2014 | Award Amount: 4.46M | Year: 2015
The overall aim is to create the foundations for commercializing an automotive derivative fuel cell system in the 50 to 100 kW range, for combined heat and power (CHP) applications in commercial and industrial buildings. More specifically, the project has the following objectives: develop system components allowing reduced costs, increased durability and efficiency build and validate a first 50 kW PEM prototype CHP system create the required value chain from automotive manufacturers to stationary energy end-users Mass-market production of fuel cells will be a strong factor in reducing first costs. In this respect, joining the forces of two non-competing sectors (automotive and stationary) will bring benefits to both, to increase production volume and ultimately reduce costs to make fuel cells competitive. As a consequence, the project partners have identified a PEM fuel cell based CHP concept to address the stationary power market, primarily for commercial and industrial buildings requiring an installed capacity from about 50 kWe to some hundreds of kWe. The main components of the system have been validated to at least laboratory scale (TRL>4). As a part of the present AutoRE proposal, the overall system will be demonstrated and further validated to increase the technology readiness level to TRL5. In addition, innovative solutions will be demonstrated to continuously improve performance and reduce costs and complexity. The project consortium reflects the full value chain of the fuel cell CHP system which will enhance significantly the route to market for the system/technology. The proposal relates to FCH-02.5-2014: Innovative fuel cell systems at intermediate power range for distributed combined heat and power generation, and it addresses the main specific challenges and scope laid down in the FCH JU AWP2014 to develop, manufacturing and validation of a new generation of fuel cell systems with properties that significantly improve competitiveness.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: SEAC-2-2014 | Award Amount: 1.50M | Year: 2015
Higher Education Institutions and Responsible Research and Innovation (HEIRRI) foster an alignment of research and innovation (R&I) with the needs, values and societal expectations. The six key aspects of Responsible Research and Innovation (RRI)-societal/public engagement, gender equality, open access, science education, ethics and governance in R&I-are transdisciplinary included at all stages of formation of scientist and engineers, and other professional fields involved in R&I. HEIRRI will create and share on OA a stock-taking inventory constituted by a State of the Art Review and a Data Base. The inventory will gather results of other EU funded RRI projects, good cases and practices of RRI and RRI Learning. Also, different stakeholders involved and/or affected by R&I will participate in a debate and reflection process on RRI Learning through online and offline Forum actions. Results from the inventory will represent the basis for RRI Training programs and formative materials, offering the students knowledge and skills to develop viable solutions to specific problems related to R&I, integrating theory and practice. They will be designed for the different HEI educational levels (undergraduate, MD and PhD, summer courses and MOOC), mainly based on Problem based learning methodology, and supported by multimedia materials (videos and microvideos, 2.0 materials, etc.). All results and products elaborated by HEIRRI will be uploaded on OA at RRITools Platform. An internationalization plan will guarantee their spreading awareness and future use by HEI from Europe and beyond. A global scope and expertise on RRI will be provided by HEIRRI consortium that consists of 5 European HEI (Universitat Pompeu Fabra (UPF), Universitetet I Bergen (UiB), Aarhus Universitet (AU), Institut Fuer Hoehere Studien und Wissenschaftliche Forschung (IHS), Sveuciliste u Splitu (University of Split, UNIST)), the European network of science centres and museums (AEESTI / Ecsite), Fundacin Bancaria Caixa Destalvis i Pensions de Barcelona La Caixa (FBLC), a network of universities (Associaci Catalana dUniversitats Pbliques, ACUP), and a private company specialized in R&I (INNOVATEC).
Agency: European Commission | Branch: FP7 | Program: CP-CSA-Infra | Phase: INFRA-2012-1.1.9. | Award Amount: 10.48M | Year: 2013
In recent years, biomedical research has crossed international borders in large, collaborative studies showing the value of multidisciplinarity and scale advantage. This has yielded valuable insights and some led to new and better medicines and treatments for diseases. However, disease-focused studies provide less insight in the real disease onset, the relative disease burden in the population, and the actual comparability of selected patients. Large prospective cohort (LPC) studies following up initially healthy participants for years or decades are considered more reliable and different diseases can be studied. LPC studies require large numbers of subjects which are costly but particularly benefited from the advent of high throughput techniques providing opportunities for powerful study designs. This project unites the large study sets of the European Biobanking and Biomolecular Research Infrastructure (BBMRI) and the International Agency for Research on Cancer (IARC), thus achieving a worldwide unique scale of integration. Specifically, we aim to:1)Evaluate/improve the harmonization of individual data on health, lifestyle and other exposures;2)Develop/implement harmonized definitions of diseases;3)Improve biobanking and research technologies and develop innovative solutions facilitating high-quality, fair access to samples and data;4)Provide free transnational access by users, through study proposals selected by an open, pan-European call;5)In the framework of these studies, generate and provide access to whole genome sequences, transcriptome, proteome, metabolome and methylome data;6)Build new public-private partnerships involving large-scale prospective cohorts, and strengthening existing ones, allowing transparent industrial access to academic expertise;7) Build a network transferring the expertise of established European large-scale biobanks to new biobank initiatives under development in other countries.
Novak I.,University of Split
Antioxidants and Redox Signaling | Year: 2012
Significance: Mitochondrial dynamics and turnover are crucial for cellular homeostasis and differentiation. The removal of damaged mitochondria that could contribute to cellular dysfunction or death is achieved through the process of mitochondrial autophagy, i.e., mitophagy. Moreover, mitophagy is responsible for removal of mitochondria during terminal differentiation of red blood cells and T cells. Recent Advances: Recent work is elucidating how mitochondria are recognized for selective mitophagy either by PINK1 and Parkin or mitophagic receptors Nix and Bnip3 and their accompanying modulators. PINK1/Parkin-mediated mitophagy reveals their role of cargo recognition through polyubiquitination of mitochondrial proteins, while Nix functions as a regulated mitophagy receptor. These recognized modes of capture by the autophagy machinery operate at different efficiencies, from partial to complete elimination of mitochondria. Critical Issues: It is critical to understand that the distinct regulatory mechanisms involve not only autophagy machinery, but also proteins associated with mitochondrial fusion and fission and therefore, regulation of mitochondrial morphology. The end result is either finely tuned quality control of damaged mitochondria, or mitochondrial clearance during development-induced mitophagy. Future Directions: In this article, known mechanisms and future directions for deciphering the challenge of mitophagy regulation will be discussed. Antioxid. Redox Signal. © 2012 Mary Ann Liebert, Inc.
Andabaka T.,University of Split
The Cochrane database of systematic reviews | Year: 2013
Respiratory syncytial virus (RSV) is one of the most important viral pathogens causing acute respiratory infections in children. It results in about 3.4 million hospitalisations annually in children under five. Palivizumab is an anti-RSV monoclonal antibody, administered intramuscularly at a dose of 15 mg/kg once every 30 days. The efficacy and safety of palivizumab has been evaluated in multicentre, randomised controlled trials (RCTs) and a large number of economic evaluations (EEs) have tested its cost-effectiveness. To assess the effectiveness and safety of palivizumab prophylaxis compared with placebo, or another type of prophylaxis, in reducing the risk of complications (hospitalisation due to RSV infection) in high-risk infants and children. To assess the cost-effectiveness (or cost-utility) of palivizumab prophylaxis compared with no prophylaxis in infants and children in different risk groups. We searched CENTRAL 2012, Issue 7, MEDLINE (1996 to July week 4, 2012), EMBASE (1996 to August 2012), CINAHL (1996 to August 2012) and LILACS (1996 to August 2012) for studies of effectiveness and safety. We searched the NHS Economic Evaluations Database (NHS EED 2012, Issue 4), Health Economics Evaluations Database (HEED, 9 August 2012) and Paediatric Economic Database Evaluations (PEDE, 1980 to 2009), MEDLINE (1996 to July week 4, 2012) and EMBASE (1996 to August 2012) for economic evaluations. We included RCTs comparing palivizumab prophylaxis with a placebo, no prophylaxis or another type of prophylaxis in preventing serious lower respiratory tract disease caused by RSV in paediatric patients at high risk. We included cost-effectiveness analyses and cost-utility analyses comparing palivizumab prophylaxis with no prophylaxis. Two review authors independently assessed risk of bias for the included studies and extracted data for both the RCTs and EEs. We calculated risk ratios (RRs) and their associated 95% confidence intervals (CIs) for dichotomous outcomes and for adverse events (AEs). We provided a narrative summary of results for continuous outcomes, due to missing data on standard deviations. We performed fixed-effect meta-analyses for the estimation of pooled effects whenever there was no indication of heterogeneity between included RCTs. We summarised the results reported in included EEs, such as incremental costs, incremental effectiveness, and incremental cost-effectiveness and/or cost-utility ratios (ICERs), and we calculated ICER present values in 2011 Euros for all studies. Of the seven available RCTs, three compared palivizumab with a placebo in a total of 2831 patients, and four compared palivizumab with motavizumab in a total of 8265 patients. All RCTs were sponsored by the drug manufacturing company. The overall quality of RCTs was good, but for most of the outcomes assessed only data from two studies contributed to the analysis. Palivizumab prophylaxis was associated with a statistically significant reduction in RSV hospitalisations (RR 0.49, 95% CI 0.37 to 0.64) when compared to placebo. When compared to motavizumab, palivizumab recipients showed a non-significant increase in the risk of RSV hospitalisations (RR 1.36, 95% CI 0.97 to 1.90). In both cases, the proportion of children with any AE or any AE related to the study drug was similar between the two groups.In terms of economic evidence, we included 34 studies that reported cost-effectiveness and/or cost-utility data for palivizumab prophylaxis compared with no prophylaxis, in high-risk children with different underlying medical conditions. The overall quality of EEs was good, but the variations in modelling approaches were considerable across the studies, leading to big differences in cost-effectiveness results. The cost-effectiveness of palivizumab prophylaxis depends on the consumption of resources taken into account by the study authors; and on the cost-effectiveness threshold set by the healthcare sector in each country. There is evidence that palivizumab prophylaxis is effective in reducing the frequency of hospitalisations due to RSV infection, i.e. in reducing the incidence of serious lower respiratory tract RSV disease in children with chronic lung disease, congenital heart disease or those born preterm.Results from economic evaluations of palivizumab prophylaxis are inconsistent, implying that economic findings must be interpreted with caution. ICER values varied considerably across studies, from highly cost-effective to not cost-effective. The availability of low-cost palivizumab would reduce its inequitable distribution, so that RSV prophylaxis would be available to the poorest countries where children are at greatest risk.